Jazz Pharmaceuticals Ireland Limited
8
5
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
12.5%
1 terminated/withdrawn out of 8 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
200%
2 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Role: collaborator
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Role: collaborator
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
Role: collaborator
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Role: collaborator
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Role: collaborator
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
Role: collaborator
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Role: collaborator
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Role: collaborator
All 8 trials loaded